ReviewOncotarget2017
Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Coffee Intake Decreases Risk of Postmenopausal Breast Cancer: A Dose-Response Meta-Analysis on Prospective Cohort Studies.Nutrients · 2018Pooled it
- Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- Persistent organic pollutants and prostate cancer: multiple mechanisms and comprehensive control strategies.Frontiers in cell and developmental biology · 2026Review
- Machine learning-driven prediction models and mechanistic insights into cardiovascular diseases: deciphering the environmental endocrine disruptors nexus.Journal of translational medicine · 2025Article
- Associations between "Cancer Risk", "Inflammation" and "Metabolic Syndrome": A Scoping Review.Biology · 2024Article
- VenomPred 2.0: A NovelJournal of chemical information and modeling · 2024Article
- Effects of Pharmaceutical Substances with Obesogenic Activity on Male Reproductive Health.International journal of molecular sciences · 2024Review
- Human Endocrine-Disrupting Effects of Phthalate Esters through Adverse Outcome Pathways: A Comprehensive Mechanism Analysis.International journal of molecular sciences · 2023Article
- Endocrine Disruptors in Food, Estrobolome and Breast Cancer.Journal of clinical medicine · 2023Review
- Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions.Molecular oncology · 2022Article
- Combined Effects of Different Endocrine-Disrupting Chemicals (EDCs) on Prostate Gland.International journal of environmental research and public health · 2021Review
- In vitro and in vivo efficacy of thiacloprid against Echinococcus multilocularis.Parasites & vectors · 2021Article
- Article
- Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report.Frontiers in immunology · 2021Article
- The Adipose Tissue at the Crosstalk Between EDCs and Cancer Development.Frontiers in endocrinology · 2021Review
- Unleashing the Diagnostic, Prognostic and Therapeutic Potential of the Neuronostatin/GPR107 System in Prostate Cancer.Journal of clinical medicine · 2020Article
- Sex-specific clustering of metabolic risk factors and cancer risk: a longitudinal study in Iran.Biology of sex differences · 2020Article
- Nutraceutical Potential ofNutrients · 2019Review
- Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome.Hormones & cancer · 2018Article
- Gendermetrics of cancer research: results from a global analysis on prostate cancer.Oncotarget · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
29 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review summarizes the main pathophysiological basis of the relationship between metabolic syndrome, endocrine disruptor exposure and prostate cancer that is the most common cancer among men in industrialized countries. Metabolic syndrome is a cluster of metabolic and hormonal factors having a central role in the initiation and recurrence of many western chronic diseases including hormonal-related cancers and it is considered as the world's leading health problem in the coming years. Many biological factors correlate metabolic syndrome to prostate cancer and this review is aimed to focus, principally, on growth factors, cytokines, adipokines, central obesity, endocrine abnormalities and exposure to specific endocrine disruptors, a cluster of chemicals, to which we are daily exposed, with a hormone-like structure influencing oncogenes, tumor suppressors and proteins with a key role in metabolism, cell survival and chemo-resistance of prostate cancer cells. Finally, this review will analyze, from a molecular point of view, how specific foods could reduce the relative risk of incidence and recurrence of prostate cancer or inhibit the biological effects of endocrine disruptors on prostate cancer cells. On the basis of these considerations, prostate cancer remains a great health problem in terms of incidence and prevalence and interventional studies based on the treatment of metabolic syndrome in cancer patients, minimizing exposure to endocrine disruptors, could be a key point in the overall management of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.